Your browser is no longer supported. Please, upgrade your browser.
EYEG EyeGate Pharmaceuticals, Inc. monthly Stock Chart
EYEG [NASD]
EyeGate Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.97 Insider Own3.00% Shs Outstand4.55M Perf Week-1.33%
Market Cap15.91M Forward P/E- EPS next Y-1.56 Insider Trans0.00% Shs Float4.44M Perf Month-6.59%
Income-8.40M PEG- EPS next Q-0.35 Inst Own41.00% Short Float0.21% Perf Quarter-18.86%
Sales0.00M P/S- EPS this Y51.20% Inst Trans-2.74% Short Ratio0.48 Perf Half Y-35.50%
Book/sh1.31 P/B2.55 EPS next Y20.00% ROA-78.80% Target Price- Perf Year-56.75%
Cash/sh0.61 P/C5.49 EPS next 5Y- ROE-112.80% 52W Range3.20 - 12.89 Perf YTD-66.72%
Dividend- P/FCF- EPS past 5Y11.50% ROI-109.20% 52W High-74.13% Beta1.17
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin- 52W Low4.22% ATR0.15
Employees10 Current Ratio3.80 Sales Q/Q- Oper. Margin- RSI (14)40.27 Volatility3.36% 4.65%
OptionableNo Debt/Eq0.00 EPS Q/Q61.60% Profit Margin- Rel Volume0.16 Prev Close3.44
ShortableYes LT Debt/Eq0.05 Earnings- Payout- Avg Volume19.58K Price3.33
Recom2.00 SMA20-1.81% SMA50-8.57% SMA200-27.62% Volume3,080 Change-3.06%
Nov-12-20Reiterated H.C. Wainwright Buy $12 → $10
Feb-06-18Reiterated H.C. Wainwright Buy $5 → $3
Apr-07-16Initiated Noble Financial Buy $10
Feb-01-16Initiated Rodman & Renshaw Buy $10
Dec-23-15Initiated Chardan Capital Markets Buy $6
Nov-12-15Initiated Maxim Group Buy $11
Nov-09-20 04:15PM  
Sep-28-20 11:05AM  
Sep-25-20 10:48AM  
Sep-08-20 06:55AM  
Aug-12-20 06:55AM  
Aug-06-20 04:15PM  
Jul-14-20 06:55AM  
Jun-11-20 06:55AM  
Jun-01-20 06:55AM  
May-19-20 09:11AM  
May-06-20 04:15PM  
09:10AM  
Apr-01-20 09:04AM  
Mar-31-20 06:55AM  
Mar-04-20 04:15PM  
Jan-06-20 06:55AM  
Jan-03-20 10:25AM  
Dec-31-19 09:25AM  
Dec-17-19 06:55AM  
Dec-02-19 06:55AM  
Nov-22-19 09:02AM  
08:37AM  
06:55AM  
Nov-14-19 10:15AM  
Nov-07-19 06:55AM  
Oct-09-19 06:55AM  
06:55AM  
Sep-30-19 06:55AM  
Sep-23-19 06:55AM  
Sep-16-19 06:55AM  
Sep-03-19 06:55AM  
Aug-29-19 12:45PM  
Aug-26-19 06:55AM  
Aug-08-19 06:55AM  
Aug-05-19 12:21PM  
09:00AM  
06:55AM  
Jul-31-19 06:55AM  
Jul-09-19 06:55AM  
Jun-26-19 06:55AM  
Jun-05-19 10:00AM  
Jun-03-19 06:55AM  
May-14-19 06:55AM  
May-08-19 04:15PM  
May-02-19 02:00PM  
06:55AM  
Mar-28-19 10:00AM  
Mar-26-19 06:55AM  
Mar-01-19 04:05PM  
Jan-29-19 06:55AM  
Jan-16-19 06:55AM  
Nov-30-18 12:30PM  
Nov-21-18 08:45AM  
Nov-14-18 11:20AM  
06:50AM  
Nov-13-18 04:05PM  
09:50AM  
06:55AM  
06:55AM  
Oct-02-18 06:55AM  
Sep-28-18 11:45AM  
Sep-25-18 06:55AM  
Sep-24-18 06:55AM  
Sep-04-18 08:31AM  
08:30AM  
Aug-29-18 08:30AM  
Aug-20-18 08:30AM  
Aug-07-18 08:30AM  
Aug-03-18 08:30AM  
Jul-26-18 09:30AM  
09:20AM  
Jul-24-18 08:30AM  
Jul-10-18 07:45AM  
Jun-22-18 08:30AM  
Jun-11-18 07:00AM  
May-30-18 08:30AM  
May-29-18 10:35AM  
May-25-18 09:37PM  
May-22-18 08:30AM  
May-16-18 04:30PM  
May-11-18 08:30AM  
May-07-18 08:11AM  
Apr-17-18 04:30PM  
Apr-13-18 07:00AM  
Apr-11-18 08:30AM  
Apr-09-18 08:30AM  
Apr-06-18 08:30AM  
Mar-09-18 08:30AM  
Mar-08-18 03:31PM  
08:30AM  
Mar-02-18 04:28PM  
Feb-21-18 11:30AM  
Feb-07-18 08:30AM  
Feb-05-18 10:20AM  
08:30AM  
Jan-19-18 06:55PM  
Jan-04-18 08:30AM  
Jan-02-18 03:19PM  
Dec-25-17 11:54AM  
Dec-19-17 08:30AM  
EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and anterior uveitis; and Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.